Int. j. adv. multidisc. res. stud. 2025; 5(6):1605-1606

Received: 07-12-2025
Accepted: 17-12-2025

International Journal of Advanced Multidisciplinary Research and Studies

ISSN: 2583-049X

Letter to the Editor

The Efficacy of acetyl-L-carnitine and Palmitoylethanolamide in Traumatic Lower Back Pain should be Tested by Appropriately Designed Studies

[1] Sinda Zarrouk, [2] Josef Finsterer

[1] Institute Pasteur of Tunis, University of Tunis El Manar and Genomic Platform, Tunisia
[2] Neurology & Neurophysiology Censer, Vienna, Austria

Corresponding Author: **Josef Finsterer**

Letter to the Editor

We read with interest the article by Cominacini *et al*. on a single-center, observational, single-arm longitudinal study on the effect of the fixed combination of acetyl-L-carnitine (ALC), palmitoylethanolamide (PEA), alpha-lipoic acid (ALA), Boswellia serrata, vitamin E, and vitamin B6 over a period of 56 days in 48 patients with traumatic low back pain [1]. This combination was found to reduce neuropathic pain, as measured by the Neuropathic Pain Scale (NPS) and the Visual Analogue Scale (VAS), and to improve physical health status according to SF-36 [1]. The study is promising, but some uncertainties should be clarified.

The first point is that it was not a single drug that was tested, but a combination of several drugs [1]. Therefore, it is impossible to say which of the drugs administered or which combination of them was truly effective. To test the effect of a drug on neuropathic pain, it is generally recommended to test each substance individually rather than as a cocktail.

The second point is that the dosages of the individual active ingredients in the cocktail were not adjusted to body weight. It is therefore conceivable that some obese patients did not experience any pain relief simply because the individual components were relatively underdosed. We should therefore know whether pain relief correlated with body weight.

The third point is that the effect of the study cocktail may also depend heavily on the type of trauma that caused the lower back pain. We should know how many of the patients included suffered a car accident, a fall, a sports accident, or trauma from heavy lifting. The response to the study cocktail may also depend on the injured structure. How many patients had soft tissue damage (tears or strains to muscles, tendons, joint capsules, or ligaments), herniated discs, or nerve compression (pinched nerves causing pain, tingling, or weakness)?

The fourth point is that the use of painkillers other than opioids was not restricted. It is therefore conceivable that the pain relief in some patients was simply due to taking a higher dose of non-steroidal anti-inflammatory drugs (NSAIDs) and not to taking the study drug. Therefore, the type of painkillers and their dosages should have been included in the study.

The fifth point is that no information was provided about liver and kidney function. Since serum levels of the administered drugs can depend heavily on liver and kidney function, we should know how many patients had kidney or liver dysfunction and therefore may have been overdosed. Did those with impaired metabolism or excretion of the study drugs perform better on the NPS and VAS scales than those with normal metabolism of the study drugs?

Finally, the study design used (single-center, single-arm, no control group, non-randomized, non-blinded) is unsuitable for testing the efficacy of the prescribed drugs. The gold standard for testing drug efficacy is the randomized, double-blind, placebo-controlled crossover study [2].

Declarations
Ethical Approval: Not applicable.

Consent to Participation: Not applicable.

Consent for Publication: Not applicable.

Funding: None received.

Availability of Data and Material: All data are available from the corresponding author.

Completing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contribution: JF was responsible for the design and conception, discussed available data with coauthors, wrote the first draft, and gave final approval. SZ: contributed to literature search, discussion, correction, and final approval.

Acknowledgements: None.

Keywords: Lower Back Pain, Neuropathic Pain, acetyl-L-carnitine, Palmitoylethanolamide, Alpha Lipoic Acid

References
1. Cominacini M, Valenti MT, Braggio M, Caramori A, Vedovi E, Dalle Carbonare L. Unlocking Relief: Investigating the Impact of a Fixed Combination of Acetyl-L-Carnitine and Palmitoylethanolamide on Traumatic Acute Low Back Pain. Eur J Neurol, Aug 2025; 32(8):e70334. Doi: 10.1111/ene.70334
2. Institute of Medicine (US) Committee on Strategies for Small-Number-Participant Clinical Research Trials; Evans CH Jr., Ildstad ST, editors. Small Clinical Trials: Issues and Challenges. Washington (DC): National Academies Press (US). 2001; 2, Design of Small Clinical Trials. Available from: https://www.ncbi.nlm.nih.gov/books/NBK223329/